<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203311434937</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203311434937</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Cytokine imbalance in systemic lupus erythematosus: a study on northern Indian subjects</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Arora</surname><given-names>V</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311434937">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Verma</surname><given-names>J</given-names></name>
<xref ref-type="aff" rid="aff2-0961203311434937">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Marwah</surname><given-names>V</given-names></name>
<xref ref-type="aff" rid="aff3-0961203311434937">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kumar</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff4-0961203311434937">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Anand</surname><given-names>D</given-names></name>
<xref ref-type="aff" rid="aff5-0961203311434937">5</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Das</surname><given-names>N</given-names></name>
<xref ref-type="aff" rid="aff5-0961203311434937">5</xref>
<xref ref-type="corresp" rid="corresp1-0961203311434937"/>
</contrib>
</contrib-group>
<aff id="aff1-0961203311434937"><label>1</label>Department of Medicine, University of Pennsylvania, Philadelphia, USA</aff>
<aff id="aff2-0961203311434937"><label>2</label>Department of Genetics, Sir Ganga Ram Hospital, New Delhi, India</aff>
<aff id="aff3-0961203311434937"><label>3</label>Department of Rheumatology, Command Hospital, Lucknow, India</aff>
<aff id="aff4-0961203311434937"><label>4</label>Department of Rheumatology, Fortis Healthcare Limited, New Delhi, India</aff>
<aff id="aff5-0961203311434937"><label>5</label>Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India</aff>
<author-notes>
<corresp id="corresp1-0961203311434937">Nibhriti Das, Department of Biochemistry, Room No. 3022, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India-29 Email: <email>nibhriti@hotmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2012</year>
</pub-date>
<volume>21</volume>
<issue>6</issue>
<fpage>596</fpage>
<lpage>603</lpage>
<history>
<date date-type="received"><day>13</day><month>2</month><year>2011</year></date>
<date date-type="accepted"><day>12</day><month>12</month><year>2011</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2012. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p><bold>Objective:</bold> The phenotype of systemic lupus erythematosus (SLE) in Asian Indians is more severe as compared with that in Caucasians. The reason is not clear. In this context, we studied serum levels of interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), interleukin-4 (IL-4) and interlekin-10 (IL-10). Their interrelations and correlation with SLEDAI scores were evaluated. <bold>Materials and methods:</bold> Forty patients with active SLE and 40 controls were studied. The mean SLEDAI score and anti-ds DNA level of the patients were 21.45 ± 8.61 and 176.68 ± 81.31 (IU/ml), respectively. Cytokines were estimated by enzyme-linked immunosorbent assay. <bold>Results:</bold> In controls, the levels of IFN-γ were highest, followed by TNF-α, IL-10 &amp; IL-4. In patients, however, the levels of TNF-α were highest, followed by IFN-γ, IL-10 &amp; IL-4. IL-10 and IL-4 correlated negatively, and IFN-γ and TNF-α correlated positively with the SLEDAI scores. As compared with controls, in patients, the mean values of TNF-α, IL-10 and TNF-α/IL-10 ratio were higher by 6.9, 2.9 and 2.3 times, respectively (<italic>p</italic> &lt; 0.001). Significant positive correlation was found between these two cytokines in patients (<italic>r</italic> = 0.327, <italic>p</italic> &lt; 0.05) but not in controls. The levels and ratio of IL-4 and IFN-γ were comparable between patients and controls. These two cytokines correlated negatively both in controls (<italic>r</italic> = −0.358, <italic>p</italic> &lt; 0.05) and patients (<italic>r</italic> = −0.990, <italic>p</italic> &lt; 0.001). The ratio of TNF-α/IL-4 was 4.2 times higher, and those of IFN-γ/IL-4 and IFN-γ/IL-10 were 1.89 and 3.40 times lower in patients as compared with controls. A positive correlation between IL-10 and IL-4 (<italic>r</italic> = 0.345, <italic>p</italic> &lt; 0.05) and a negative correlation between IL-10 and IFN-γ (<italic>r</italic> = −0.382, <italic>p</italic> &lt; 0.05) were observed only in patients. <bold>Conclusion:</bold> This study showed a distinct profile of cytokine imbalance in patients with SLE from the northern plains of India. The levels, ratios and correlations of cytokines in patients suggested significant deviation from normal. Correlations of cytokines with SLEDAI scores indicated that TNF-α contributes significantly to the pathological manifestations of SLE in patients from the region. A detailed study is warranted.</p>
</abstract>
<kwd-group>
<kwd>Systemic lupus erythematosus</kwd>
<kwd>tumor necrosis factor-alpha</kwd>
<kwd>interleukin 10</kwd>
<kwd>interferon-gamma</kwd>
<kwd>interleukin-4</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203311434937" sec-type="intro"><title>Introduction</title>
<p>Systemic lupus erythematosus (SLE) is characterized by multisystem involvement and autoantibodies to nuclear, cytoplasmic and cell-surface auto antigens.<sup><xref ref-type="bibr" rid="bibr1-0961203311434937">1</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr3-0961203311434937">3</xref></sup> The etiology is as yet unknown and the pathogenesis is complex, involving immunological, genetic, hormonal and environmental precipitating factors. The disease shows a striking preponderance in females and affects predominantly women in their reproductive years, probably due to an estrogen hormonal effect.<sup><xref ref-type="bibr" rid="bibr4-0961203311434937">4</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr6-0961203311434937">6</xref></sup> The prevalence of SLE varies between ethnic groups, being approximately 1:250 among black women, 1:1000 in Chinese women and 1:4300 in white women.<sup><xref ref-type="bibr" rid="bibr7-0961203311434937">7</xref></sup> SLE is rare in India.</p>
<p>In India, the median age of onset of SLE is 24.5 years and the sex ratio (F:M) is 11:1 as reported by Kumar et al.<sup><xref ref-type="bibr" rid="bibr8-0961203311434937">8</xref></sup> Since 1895, when the first case of SLE was reported from India, the disease has been extensively studied in different regions of the country, including Chennai, Calcutta, Mumbai and New Delhi.<sup><xref ref-type="bibr" rid="bibr9-0961203311434937">9</xref></sup> A prevalence study in India (carried out in a rural population near Delhi) found a point prevalence of 3 per 100,000.<sup><xref ref-type="bibr" rid="bibr10-0961203311434937">10</xref></sup> However, studies in the UK have shown a prevalence of SLE about three times higher in Asian Indians residing there as compared with the white population.<sup><xref ref-type="bibr" rid="bibr11-0961203311434937">11</xref></sup> This provides a timely alarm, as lifestyles and other environmental factors in India are at a stage of rapid transition, coming closer to those of western people.</p>
<p>The prognosis of patients with SLE varies, depending on the organ systems most affected and the severity of inflammation. Some patients have long periods of time with mild or absent symptoms. There is a 90–95% patient survival rate after 2 years from diagnosis of the disease, a 82–90% survival rate after 5 years with the disease, a 71–80% survival rate after 10 years and 63–75% after 20 years. A number of demographic features such as gender, age at onset, race and socioeconomic status may be predictive for mortality in patients with SLE. The 5-year mortality of SLE patients was above 50% in the 1950s;<sup><xref ref-type="bibr" rid="bibr12-0961203311434937">12</xref></sup> however, within the last decade it has come down to less than 10%.<sup><xref ref-type="bibr" rid="bibr13-0961203311434937">13</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr17-0961203311434937">17</xref></sup> The Indian figures for survival rates are still grim (50–60% survival at 10 years).<sup><xref ref-type="bibr" rid="bibr18-0961203311434937">18</xref>,<xref ref-type="bibr" rid="bibr19-0961203311434937">19</xref></sup> Possible reasons for poor survival in the Indian SLE population include delay in diagnosis, referral bias (only the most serious cases are referred by practitioners), suboptimal health care facilities, infection such as endemic tuberculosis, and an inherently more severe disease.<sup><xref ref-type="bibr" rid="bibr8-0961203311434937">8</xref></sup></p>
<p>Nephritis is one of the most severe complications of this disease. A review based on clinical and laboratory findings in Indian patients with SLE showed a higher proportion of alopecia, renal lupus, oral ulcers and neurological involvement, reaching statistically significant levels when compared with other racial groups.<sup><xref ref-type="bibr" rid="bibr9-0961203311434937">9</xref></sup> Another study from the UK showed a higher prevalence of lupus nephritis in Indo-Asians as compared with European whites.<sup><xref ref-type="bibr" rid="bibr20-0961203311434937">20</xref></sup> Renal, neurological and muscular symptoms are much more prevalent in the northern Indians as compared with other regions of India.<sup><xref ref-type="bibr" rid="bibr9-0961203311434937">9</xref></sup> The molecular pathogenesis which may account for differences in disease phenotypes in people from different geographic regions remains unknown. Better insight into each of the different aspects of the disease and related factors is hence needed in SLE.</p>
<p>Cytokines control the immune responses.<sup><xref ref-type="bibr" rid="bibr5-0961203311434937">5</xref></sup> Cytokine production is not only changed in patients with SLE when compared with healthy controls, but also changes with different disease phenotypes.<sup><xref ref-type="bibr" rid="bibr21-0961203311434937">21</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr23-0961203311434937">23</xref></sup> The effects of cytokines in autoimmune diseases such as SLE cannot be consistently predicted; their effects are much more complex than the simplistic Th1 vs. Th2 definition dictates.<sup><xref ref-type="bibr" rid="bibr24-0961203311434937">24</xref></sup> The regulatory interlinks among various Th1 and Th2 cytokines can predominantly be demonstrated in animal models and in vitro culture studies.<sup><xref ref-type="bibr" rid="bibr25-0961203311434937">25</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr27-0961203311434937">27</xref></sup> The predominance of the Th1 effect is well accepted for rheumatoid arthritis, but in SLE the situation is not so clear.<sup><xref ref-type="bibr" rid="bibr28-0961203311434937">28</xref>,<xref ref-type="bibr" rid="bibr29-0961203311434937">29</xref></sup> In this context, we conducted a case-control study involving volunteers from the northern plains of India. Serum levels of cytokines, their ratios, interrelations and correlations with the SLEDAI scores were determined.</p></sec>
<sec id="sec2-0961203311434937" sec-type="materials|methods"><title>Materials and methods</title>
<sec id="sec3-0961203311434937"><title>Study subjects</title>
<p>In total, 40 patients with SLE and 40 healthy volunteers were enrolled for the study. Controls were healthy volunteers with no history of autoimmune disorders, major infection and other inflammatory diseases. Patients were selected from the outpatient department and wards of Medicine and Nephrology Department, All India Institute of Medical Sciences, New Delhi. The group consisted of 40 females. The patients were matched as closely as possible for age, sex, lifestyle and geographical lineage with controls, excepting that they were suffering from SLE. The details of the patients remained encoded until the study had progressed to a decisive end.</p>
<p>Diagnosis was made according to the criteria proposed by the American Rheumatism Association for the classification of SLE.<sup><xref ref-type="bibr" rid="bibr30-0961203311434937">30</xref>,<xref ref-type="bibr" rid="bibr31-0961203311434937">31</xref></sup> The patients fulfilled at least four of the criteria either simultaneously or over a period of time. Study subjects were all females with the mean age of 27 ± 4.6 years. Written consent was obtained from each individual before taking blood. The study was approved by the Ethics Committee of the All India Institute of Medical Sciences.</p></sec>
<sec id="sec4-0961203311434937"><title>Sample collection</title>
<p>Venous blood (5–6 ml) without anticoagulant was drawn from the controls and patients with SLE. After collection, whole blood was allowed to stand for 30 min and centrifuged at 500 <italic>g</italic>. Serum was separated and stored immediately in aliquots at −70°C until use. The serum thus prepared from each of the blood samples was used for the estimation of cytokines.</p></sec>
<sec id="sec5-0961203311434937"><title>Estimation of cytokines</title>
<p>The levels of cytokines (IFN-γ, TNF-α, IL-10 and IL-4) in serum were determined by using a solid-phase enzyme-linked immunosorbent assay (ELISA) kit (Quantikine ELISA kit, R&amp;D Systems, Minneapolis, MN, USA).</p>
<p>To the pre-coated microplates (monoclonal mouse anti-human TNF-α, IL-4, IL-10 and polyclonal anti-human IFN-γ), assay diluent was added. After 1 h, each well was aspirated and standards and samples (appropriate dilutions) were pipetted into the wells. After 2 h, the plate was washed three times with wash buffer. After washing, detection antibody (polyclonal antibody against TNF-α, IL-4, IL-10 and IFN-γ conjugated with horseradish peroxidase), was added to each well and incubated for 2 h. Again after washing, substrate solution was added, incubated for 20 min and the stop solution was then added. The optical density of each well was determined immediately at 450 nm. Assays were performed according to the manufacturer’s recommendations. The lower detection limit of the assay for IFN-γ, TNF-α, IL-10 and IL-4 was 8.0 pg/ml, 1.6 pg/ml, 3.9 pg/ml and 10 pg/ml, respectively.</p></sec>
<sec id="sec6-0961203311434937"><title>Statistical analysis</title>
<p>Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) Statistical Software for Windows, Version 16.0 (SPSS Inc, IL, USA). The results are presented as means ± standard deviation (SD). The difference in the averages between the study groups was examined by the Mann–Whitney test. Correlation coefficient between the test parameters was assessed by applying Spearman’s rank correlation test and the significance level was measured by two-tailed paired student’s <italic>t</italic>-test. A probability value of <italic>p</italic> ≤ 0.05 was considered to be statistically significant.</p></sec></sec>
<sec id="sec7-0961203311434937" sec-type="results"><title>Results</title>
<sec id="sec8-0961203311434937"><title>Levels of cytokines and their correlations in healthy individuals (controls) and patients</title>
<p>The levels of various cytokines IL-4, IFN-γ, IL-10 and TNF-α in serum were determined in 40 controls and 40 patients. The levels of TNF-α and IL-10 increased significantly (<italic>p</italic> &lt; 0.001) in patients as compared with controls. Mean levels of TNF-α were 6.9 times higher in patients (632.72 ± 118.36 pg/ml) as compared with controls (91.43 ± 30.91 pg/ml) (<xref ref-type="fig" rid="fig1-0961203311434937">Figure 1</xref>). The mean values of IL-10 were 2.9 times higher in patients (196.81 ± 75.84 pg/ml) than in controls (66.24 ± 29.75 pg/ml) (<xref ref-type="fig" rid="fig2-0961203311434937">Figure 2</xref>). The TNF-α/IL-10 ratio increased in patients (3.21) as compared with the controls (1.38, <italic>p</italic> &lt; 0.001) (<xref ref-type="table" rid="table1-0961203311434937">Table 1</xref>).
<fig id="fig1-0961203311434937" position="float"><label>Figure 1</label><caption><p>Levels of TNF-α in controls (<italic>n</italic> = 40) and patients (<italic>n</italic> = 40). Each symbol denotes one control (rhombus) or patient (square) and the bar within each group represents the mean values. <italic>p-</italic>value as indicated was calculated by Mann–Whitney test.</p></caption><graphic xlink:href="10.1177_0961203311434937-fig1.tif"/></fig>
<fig id="fig2-0961203311434937" position="float"><label>Figure 2</label><caption><p>Levels of IL-10 in controls (<italic>n</italic> = 40) and patients (<italic>n</italic> = 40). Each symbol denotes one control (rhombus) or patient (square) and the bar within each group represents the mean values. <italic>p-</italic>value as indicated was calculated by Mann–Whitney test.</p></caption><graphic xlink:href="10.1177_0961203311434937-fig2.tif"/></fig>
<table-wrap id="table1-0961203311434937" position="float"><label>Table 1</label><caption><p>Ratios of cytokines in controls and patients</p></caption>
<graphic alternate-form-of="table1-0961203311434937" xlink:href="10.1177_0961203311434937-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Cytokines ratio</th>
<th>Controls</th>
<th>Patients</th>
<th>Significance</th></tr></thead>
<tbody align="left">
<tr>
<td>TNF-α/IL-10</td>
<td>1.38</td>
<td>3.21</td>
<td>0.001</td></tr>
<tr>
<td>IFN-γ/IL-10</td>
<td>6.70</td>
<td>1.95</td>
<td>0.0001</td></tr>
<tr>
<td>TNF-α/IL-4</td>
<td>21.61</td>
<td>91.03</td>
<td>0.0001</td></tr>
<tr>
<td>IFN-γ/ IL-4</td>
<td>105.01</td>
<td>55.48</td>
<td>0.0001</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203311434937"><p>The correlation was calculated by Spearman’s rho analysis. and significance was evaluated by two-tailed test (***<italic>p</italic> &lt; 0.001, ****<italic>p</italic>&lt; 0.001).</p></fn></table-wrap-foot>
</table-wrap></p>
<p>The levels of other two cytokines, IL-4 and IFN-γ remained comparable with the controls (Figures <xref ref-type="fig" rid="fig3-0961203311434937">3</xref> and <xref ref-type="fig" rid="fig4-0961203311434937">4</xref>). The ratio of TNF-α/ IL-4 was 4.2 times higher in patients (91.03) as compared with that in the controls (21.61, <italic>p</italic> &lt; 0.0001). The ratios of IFN-γ/IL-4 and IFN-γ/IL-10 were found to be decreased in patients (55.48 and 1.95, respectively) as compared with controls (105.01 and 6.70, respectively) (<italic>p</italic> &lt; 0.0001) (<xref ref-type="table" rid="table1-0961203311434937">Table 1</xref>).
<fig id="fig3-0961203311434937" position="float"><label>Figure 3</label><caption><p>Levels of IL-4 in controls (<italic>n</italic> = 40) and patients (<italic>n</italic> = 40). Each symbol denotes one control (rhombus) or patient (square) and the bar within each group represents the mean values. <italic>p-</italic>values as calculated by Mann–Whitney test were insignificant.</p></caption><graphic xlink:href="10.1177_0961203311434937-fig3.tif"/></fig>
<fig id="fig4-0961203311434937" position="float"><label>Figure 4</label><caption><p>Levels of IFN-γ in controls (<italic>n</italic> = 40) and patients (<italic>n</italic> = 40). Each symbol denotes one control (rhombus) or patient (square) and the bar within each group represents the mean values. <italic>p</italic> values as calculated by Mann-Whitney test were insignificant.</p></caption><graphic xlink:href="10.1177_0961203311434937-fig4.tif"/></fig></p>
<p><xref ref-type="table" rid="table2-0961203311434937">Table 2</xref> shows the correlations amongst various cytokines in controls and patients. A significant positive correlation (<italic>r</italic> = 0.327, <italic>p</italic> &lt; 0.05) was observed between the levels of IL-10 and TNF-α in patients but not in controls. The correlation between IL-10 versus IL-4 (<italic>r</italic> = 0.345, <italic>p</italic> &lt; 0.05) was positive, and that between IL-10 versus IFN-γ (<italic>r</italic> = −0.382, <italic>p</italic> &lt; 0.05) was negative in patients but not in controls. Levels of IL-4 and IFN-γ gave a significant (<italic>p</italic> &lt; 0.001) negative correlation both in controls (<italic>r</italic> = −0.358, <italic>p</italic> &lt; 0.05) and patients (<italic>r</italic> = −0.990, <italic>p</italic> &lt; 0.001). The correlation plots are shown in <xref ref-type="fig" rid="fig5-0961203311434937">Figure 5</xref>.
<fig id="fig5-0961203311434937" position="float"><label>Figure 5</label><caption><p>Correlations among various cytokines. (<italic>A</italic>) Correlation between levels of TNF-α and IL-10 in patients (<italic>n</italic> = 40). (<italic>B</italic>) Correlation between IL-4 and IL-10 in patients (<italic>n</italic> = 40). (<italic>C</italic>) Correlation between IFN-γ and IL-10 in patients (<italic>n</italic> = 40). (<italic>D</italic>) Correlation between IL-4 and IFN-γ both in controls (<italic>n</italic> = 40) and patients (<italic>n</italic> = 40). The <italic>r</italic> values were calculated by Spearman’s rho analysis and <italic>p-</italic>values as indicated were calculated by two-tailed test (*<italic>p</italic> ≤ 0.05, *** <italic>p</italic> ≤ 0.001).</p></caption><graphic xlink:href="10.1177_0961203311434937-fig5.tif"/></fig>
<table-wrap id="table2-0961203311434937" position="float"><label>Table 2</label><caption><p>Correlations amongst various cytokines in controls and patients</p></caption>
<graphic alternate-form-of="table2-0961203311434937" xlink:href="10.1177_0961203311434937-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Correlation amongst</th>
<th/>
<th>Controls</th>
<th/>
<th>Patients</th></tr>
<tr><th>Cytokines</th>
<th>Correlation</th>
<th>Significance</th>
<th>Correlation</th>
<th>Significance</th></tr>
<tr><th/>
<th/>
<th>(2-tailed)</th>
<th/>
<th>(2-tailed)</th></tr></thead>
<tbody align="left">
<tr>
<td>IL-10-TNF-α</td>
<td>−0.167</td>
<td>0.322</td>
<td>0.327</td>
<td>0.048<xref ref-type="table-fn" rid="table-fn2-0961203311434937">*</xref></td></tr>
<tr>
<td>IL10-IL4</td>
<td>0.247</td>
<td>0.214</td>
<td>0.345</td>
<td>0.036<xref ref-type="table-fn" rid="table-fn2-0961203311434937">*</xref></td></tr>
<tr>
<td>IL-10-IFN-γ</td>
<td>−0.247</td>
<td>0.191</td>
<td>−0.382</td>
<td>0.020<xref ref-type="table-fn" rid="table-fn2-0961203311434937">*</xref></td></tr>
<tr>
<td>TNFα-IL4</td>
<td>0.070</td>
<td>0.680</td>
<td>0.140</td>
<td>0.408</td></tr>
<tr>
<td>TNFα-IFNγ</td>
<td>0.078</td>
<td>0.646</td>
<td>0.130</td>
<td>0.444</td></tr>
<tr>
<td>IL4-IFNγ</td>
<td>−0.358</td>
<td>0.035</td>
<td>−0.990</td>
<td>0.001<xref ref-type="table-fn" rid="table-fn2-0961203311434937">***</xref></td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0961203311434937"><p>The correlation was calculated by Spearman’s rho analysis and significance was evaluated by two-tailed test (*<italic>p</italic> &lt; 0.05, ***<italic>p</italic> &lt; 0.001).</p></fn></table-wrap-foot>
</table-wrap></p>
<p><xref ref-type="table" rid="table3-0961203311434937">Table 3</xref> shows the correlations of the cytokines with SLEDAI scores. SLEDAI scores correlated positively with the levels of IFN-γ (<italic>r</italic> = 0.583, <italic>p</italic> &lt; 0.0001), TNF-α (<italic>r</italic> = 0.567, p &lt; 0.0001) and negatively with the levels of IL-4 (<italic>r</italic> = −0.541, <italic>p</italic> &lt; 0.001) and IL-10 (<italic>r</italic> = −0.747, <italic>p</italic> &lt; 0.0001).
<table-wrap id="table3-0961203311434937" position="float"><label>Table 3</label><caption><p>Correlations of SLEDAI with cytokine levels in patients</p></caption>
<graphic alternate-form-of="table3-0961203311434937" xlink:href="10.1177_0961203311434937-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Correlation with SLEDAI</th>
<th>Correlation</th>
<th>Significance (2-tailed)</th></tr></thead>
<tbody align="left">
<tr>
<td>TNF-α</td>
<td>0.567</td>
<td>0.0001<xref ref-type="table-fn" rid="table-fn3-0961203311434937">***<italic>*</italic></xref></td></tr>
<tr>
<td>IL-10</td>
<td>−0.747</td>
<td>0.0001<xref ref-type="table-fn" rid="table-fn3-0961203311434937">***<italic>*</italic></xref></td></tr>
<tr>
<td>IL-4</td>
<td>−0.541</td>
<td>0.001<xref ref-type="table-fn" rid="table-fn3-0961203311434937">***</xref></td></tr>
<tr>
<td>IFN-γ</td>
<td>0.583</td>
<td>0.0001<xref ref-type="table-fn" rid="table-fn3-0961203311434937">***<italic>*</italic></xref></td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0961203311434937"><p>The correlation was calculated by Spearman’s rho analysis and significance was evaluated by two-tailed test. (***<italic>p</italic> &lt; 0.001, ***<italic>*p</italic> &lt; 0.0001).</p></fn></table-wrap-foot>
</table-wrap></p></sec></sec>
<sec id="sec9-0961203311434937" sec-type="discussion"><title>Discussion</title>
<p>Several studies have investigated the cytokine profiles of SLE patients in vivo and in vitro. Of all the cytokines, serum levels of IL-10 were consistently reported to increase in SLE.<sup><xref ref-type="bibr" rid="bibr32-0961203311434937">32</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr36-0961203311434937">36</xref></sup> The profiles for other cytokines have been inconsistent.<sup><xref ref-type="bibr" rid="bibr37-0961203311434937">37</xref></sup> IL-10 has recently been suggested as a marker of SLE.<sup><xref ref-type="bibr" rid="bibr35-0961203311434937">35</xref></sup></p>
<p>In the present case-control study involving 40 patients with active SLE and 40 controls, we found a significant increase in the levels of IL-10 in the patients. IL-10 is a Th2 cytokine that increases B-cell proliferation, and inhibits different IFN-γ-stimulated monocyte functions including major histocompatibility complex class II antigen expression,<sup><xref ref-type="bibr" rid="bibr38-0961203311434937">38</xref></sup> H<sub>2</sub>O<sub>2</sub> production, nitric oxide synthesis,<sup><xref ref-type="bibr" rid="bibr39-0961203311434937">39</xref></sup> generation of TNF-α and microbicidal activity.<sup><xref ref-type="bibr" rid="bibr40-0961203311434937">40</xref>,<xref ref-type="bibr" rid="bibr41-0961203311434937">41</xref></sup> However, like IFN-γ, it also increases FcγRI surface expression and antibody-dependent cellular cytotoxicity in human monocytes.<sup><xref ref-type="bibr" rid="bibr42-0961203311434937">42</xref></sup> In addition to the Th2 subset of CD4+ helper cells, IL-10 is also produced by some activated B cells, some Th1 cells (in humans), activated macrophages, and some non-hematopoietic sources (e.g. keratinocytes, colon carcinoma, melanoma cells).<sup><xref ref-type="bibr" rid="bibr43-0961203311434937">43</xref></sup> In animal models, IL-10 was shown to aggravate the pathogenesis of SLE.<sup><xref ref-type="bibr" rid="bibr44-0961203311434937">44</xref>,<xref ref-type="bibr" rid="bibr45-0961203311434937">45</xref></sup> It has been shown that IgG production by B-lymphocytes from patients with SLE is largely IL-10 dependent.<sup><xref ref-type="bibr" rid="bibr46-0961203311434937">46</xref></sup> Treatment of NZB/WF1 mice with anti-IL-10 mAb delayed the onset of autoimmune manifestations and the production of autoantibodies.<sup><xref ref-type="bibr" rid="bibr44-0961203311434937">44</xref></sup></p>
<p>We found a significant negative correlation between the levels of IL-10 and SLEDAI scores. This finding however, was different from some of the earlier observations in human subjects. Park et al. reported elevated levels of serum IL-10 in SLE patients which correlated well with SLE disease activity.<sup><xref ref-type="bibr" rid="bibr47-0961203311434937">47</xref></sup> A recent study from Egypt showed an insignificant increase in serum levels of IL-10 in patients with SLE. The same study, however, documented an intimate relationship between the SLEDAI scores and levels of IL-10 in patients with SLE.<sup><xref ref-type="bibr" rid="bibr48-0961203311434937">48</xref></sup> Although IL-10 increases B-cell proliferation and hence is implicated for autoantibody generation in SLE, it has a strong anti-inflammatory role.<sup><xref ref-type="bibr" rid="bibr49-0961203311434937">49</xref></sup> This may relate to the negative correlation between the levels of IL-10 and SLEDAI scores observed in our patients.</p>
<p>Many of the functions of the immune system are affected synergistically by IL-4 and IL-10.<sup><xref ref-type="bibr" rid="bibr50-0961203311434937">50</xref></sup> Both increases and decreases in serum levels of IL-4 have been reported in SLE.<sup><xref ref-type="bibr" rid="bibr35-0961203311434937">35</xref>,<xref ref-type="bibr" rid="bibr51-0961203311434937">51</xref></sup></p>
<p>We did not find any significant difference in the mean levels of IL-4 between the patients and the controls. Like IL-10, it correlated negatively with SLEDAI scores. Several studies have found increased serum levels of IFN-γ<sup><xref ref-type="bibr" rid="bibr35-0961203311434937">35</xref>,<xref ref-type="bibr" rid="bibr52-0961203311434937">52</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr56-0961203311434937">56</xref></sup> and TNF-α<sup><xref ref-type="bibr" rid="bibr52-0961203311434937">52</xref>,<xref ref-type="bibr" rid="bibr57-0961203311434937">57</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr62-0961203311434937">62</xref></sup> in patients with active stages of SLE. Other studies have found TNF-α<sup><xref ref-type="bibr" rid="bibr22-0961203311434937">22</xref></sup> and IFN-γ<sup><xref ref-type="bibr" rid="bibr32-0961203311434937">32</xref>,<xref ref-type="bibr" rid="bibr33-0961203311434937">33</xref></sup> levels unaltered in the disease course.</p>
<p>We did not find any significant difference in the levels of IFN-γ in patients compared with controls, but the levels of IFN-γ correlated positively with the SLEDAI scores.</p>
<p>A number of effects mediated by IFN-γ are through the expression of TNF-α. TNF-α is released from monocytes/macrophages, T lymphocytes, neutrophils and mast cells stimulated by IFN-γ <sup><xref ref-type="bibr" rid="bibr63-0961203311434937">63</xref></sup> High levels of this cytokine generate systemic effects that include the induction of fever, synthesis of acute-phase proteins, and cachexia. It also causes intravascular thrombosis and shock.<sup><xref ref-type="bibr" rid="bibr64-0961203311434937">64</xref>,<xref ref-type="bibr" rid="bibr65-0961203311434937">65</xref></sup></p>
<p>It was interesting to note that despite high levels of IL-10 with no change in the levels of IFN-γ, TNF-α increased by 6.9-fold in our patients as compared with controls. TNF-α is known to diminish IL-10 production.<sup><xref ref-type="bibr" rid="bibr26-0961203311434937">26</xref></sup></p>
<p>In our patients, the TNF-α/IL-10 and TNF-α/IL-4 ratios were higher as compared with controls. This finding was similar to the findings of a correlative study on cytokines in patients with SLE from Egypt. The study suggested predominance of the Th1 cytokines over Th2.<sup><xref ref-type="bibr" rid="bibr61-0961203311434937">61</xref></sup> We observed significant positive correlations of TNF-α with SLEDAI scores. In SLE, TNF-α has been implicated in exaggerated inflammation. Open-label data suggested that TNF-α blockade suppresses inflammatory manifestations of SLE, and long-term benefit was seen in patients with lupus nephritis. A controlled clinical trial is under way.<sup><xref ref-type="bibr" rid="bibr66-0961203311434937">66</xref></sup> At the same time, in some experimental models, blockade of TNF-α transiently enhanced the production of anti-phospholipid and anti-chromatin antibodies.</p>
<p>In our patients, the correlation between TNF-α and IL-10 was positive. Levels of IL-10 correlated negatively with the levels of IFN-γ in patients but not in controls. We also found a significant positive correlation between IL-4 and IL-10 in patients but not in controls. Ratios of the IFN-γ/IL-4 and IFN-γ/IL-10 were found to be decreased in patients. This may suggest predominance of these two Th2 cytokines over IFN-γ in our patients. Overall, the scenario suggests a deviation from the normal profiles, ratios and correlations of cytokines in SLE. Th1/Th2 imbalance has been suggested to play a role in the etiopathogenesis of SLE by some investigaters.<sup><xref ref-type="bibr" rid="bibr67-0961203311434937">67</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr70-0961203311434937">70</xref></sup> Akahoshi et al., however, suggested an absence of Th1/Th2 imbalance in SLE.<sup><xref ref-type="bibr" rid="bibr71-0961203311434937">71</xref></sup> The levels and correlations between IFN-γ and IL-4 in our patients were comparable with those seen in controls, which does not reflect any significant Th1/Th2 imbalance. In addition to T-lymphocytes, IL-10 and TNF-α both are released from monocytes and activated macrophages.<sup><xref ref-type="bibr" rid="bibr43-0961203311434937">43</xref>,<xref ref-type="bibr" rid="bibr63-0961203311434937">63</xref></sup> A regulatory failure at the level of these cells may account for abnormal cytokine profiles in our patients. Peripheral blood mononuclear cells from SLE patients spontaneously release large amounts of IL-10.<sup><xref ref-type="bibr" rid="bibr72-0961203311434937">72</xref></sup></p>
<p>When cytokines levels are measured in serum, it is not possible to determine the origin of these cytokines. The serum cytokine concentrations are altered by several processes such as the production, tissue/cellular deposition, degradation, and elimination of these molecules.<sup><xref ref-type="bibr" rid="bibr73-0961203311434937">73</xref></sup> In-depth studies at the cellular level are therefore needed to explain our data.</p>
<p>A prevalence study in India carried out in a rural population near Delhi found a point prevalence of 3 per 100,000.<sup><xref ref-type="bibr" rid="bibr10-0961203311434937">10</xref></sup> This is a much lower figure than reported from the West, varying from 12.5 per 100,000 adults in England to 39 per 100,000 in Finland and 124 per 100,000 in the USA.<sup><xref ref-type="bibr" rid="bibr8-0961203311434937">8</xref></sup></p>
<p>Since the disease is rare, it was extremely difficult to obtain a larger number of blood samples for this study. Furthermore, it is difficult to get samples at different time points, as the number of willing participants declines with time. Our study therefore was limited to a small sample size, and levels of cytokines could not be monitored at different time points.</p>
<p>To conclude, this case-control study, the first of its kind, showed a distinct profile of cytokine imbalance in patients with SLE from India. We found a simultaneous and significant increase in the serum levels of TNF-α and IL-10 in the patients. Ratios of IFN-γ/IL4 and IL-10 decreased, and those of TNF-α/IL-4 and IL-10 increased with no significant change in the levels of IFN-γ and IL4 and their correlations. These findings, along with significant positive correlations of TNF-α with the SLEDAI scores, suggest that the inflammatory reactions of TNF-α cytokines contribute significantly to the pathological manifestations of SLE in patients from the region. The mechanistic aspects however, remain unclear.</p>
<p>A detailed study with a larger number of study subjects and serial follow-up is warranted to gain further insight into the role of cytokines in determining the disease phenotype in Asian Indians.</p></sec>
</body>
<back><ack>
<title>Acknowledgements</title>
<p>We would like to thank the Department of Biostatistics for their invaluable assistance in the statistical analysis. We also thank all the healthy subjects and the patients for providing their precious blood for the study.</p></ack>
<sec id="sec10-0961203311434937"><title>Funding</title>
<p>This work was supported by Council of Scientific and Industrial Research (CSIR) [grant number C600] and University grant commission (UGC) [grant number N045], New Delhi, India.</p></sec>
<sec id="sec11-0961203311434937"><title>Conflict of interest</title>
<p>The authors declare that they have no conflicts of interest.</p></sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203311434937"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>C</given-names></name><name><surname>Isenberg</surname><given-names>DA</given-names></name></person-group>. <article-title>Aetiology and pathology of systemic lupus erythematosus</article-title>. <source>Hospital Pharm</source> <year>2001</year>; <volume>8</volume>: <fpage>62</fpage>–<lpage>68</lpage>.</citation></ref>
<ref id="bibr2-0961203311434937"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HA</given-names></name><name><surname>Chung</surname><given-names>JW</given-names></name><name><surname>Park</surname><given-names>HJ</given-names></name><etal/></person-group>. <article-title>An antinuclear antibody-negative patient with lupus nephritis</article-title>. <source>Korean J Intern Med</source> <year>2009</year>; <volume>24</volume>: <fpage>76</fpage>–<lpage>79</lpage>.</citation></ref>
<ref id="bibr3-0961203311434937"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heinlen</surname><given-names>LD</given-names></name><name><surname>McClain</surname><given-names>MT</given-names></name><name><surname>Ritterhouse</surname><given-names>LL</given-names></name><etal/></person-group>. <article-title>60 kD Ro and nRNP A frequently initiate human lupus autoimmunity</article-title>. <source>PLoS One</source> <year>2010</year>; <volume>5</volume>: <fpage>e9599</fpage>–<lpage>e9599</lpage>.</citation></ref>
<ref id="bibr4-0961203311434937"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rood</surname><given-names>MJ</given-names></name><name><surname>van der Velde</surname><given-names>EA</given-names></name><name><surname>Ten Cate</surname><given-names>R</given-names></name><name><surname>Breedveld</surname><given-names>FC</given-names></name><name><surname>Huizinga</surname><given-names>TWJ</given-names></name></person-group>. <article-title>Female sex hormones at the onset of systemic lupus erythematosus affect survival</article-title>. <source>Br J Rheumatol</source> <year>1998</year>; <volume>37</volume>: <fpage>1008</fpage>–<lpage>1010</lpage>.</citation></ref>
<ref id="bibr5-0961203311434937"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Sugino</surname><given-names>H</given-names></name><name><surname>Nishimoto</surname><given-names>N</given-names></name></person-group>. <article-title>Cytokine networks in systemic lupus erythematosus</article-title>. <source>J Biomed Biotechnol</source> <year>2010</year>; <volume>2010</volume>: <fpage>676284</fpage>–<lpage>676288</lpage>.</citation></ref>
<ref id="bibr6-0961203311434937"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sekigawa</surname><given-names>I</given-names></name><name><surname>Fujishiro</surname><given-names>M</given-names></name><name><surname>Yamaguchi</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>A new hypothesis of the possible mechanisms of gender differences in systemic lupus erythematosus</article-title>. <source>Clin Exp Rheumatol</source> <year>2010</year>; <volume>28</volume>: <fpage>419</fpage>–<lpage>423</lpage>.</citation></ref>
<ref id="bibr7-0961203311434937"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dean</surname><given-names>GS</given-names></name><name><surname>Tyrrell-Price</surname><given-names>J</given-names></name><name><surname>Crawley</surname><given-names>E</given-names></name><name><surname>Isenberg</surname><given-names>DA</given-names></name></person-group>. <article-title>Cytokines and systemic lupus erythematosus</article-title>. <source>Ann Rheum Dis</source> <year>2000</year>; <volume>59</volume>: <fpage>243</fpage>–<lpage>251</lpage>.</citation></ref>
<ref id="bibr8-0961203311434937"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A</given-names></name></person-group>. <article-title>Indian guidelines on the management of SLE</article-title>. <source>J Indian Rheumatol Assoc</source> <year>2002</year>; <volume>10</volume>: <fpage>80</fpage>–<lpage>96</lpage>.</citation></ref>
<ref id="bibr9-0961203311434937"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malaviya</surname><given-names>AN</given-names></name><name><surname>Chandrasekaran</surname><given-names>AN</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Shamar</surname><given-names>PN</given-names></name></person-group>. <article-title>Systemic lupus erythematosus in India</article-title>. <source>Lupus</source> <year>1997</year>; <volume>6</volume>: <fpage>690</fpage>–<lpage>700</lpage>.</citation></ref>
<ref id="bibr10-0961203311434937"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malaviya</surname><given-names>AN</given-names></name><name><surname>Singh</surname><given-names>RR</given-names></name><name><surname>Singh</surname><given-names>YN</given-names></name><name><surname>Kapoor</surname><given-names>SK</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name></person-group>. <article-title>Prevalence of systemic lupus erythematosus in India</article-title>. <source>Lupus</source> <year>1993</year>; <volume>2</volume>: <fpage>115</fpage>–<lpage>118</lpage>.</citation></ref>
<ref id="bibr11-0961203311434937"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Samanta</surname><given-names>A</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Feehally</surname><given-names>J</given-names></name><name><surname>Symmons</surname><given-names>DP</given-names></name></person-group>. <article-title>The prevalence of diagnosed systemic lupus erythematosus in whites and Indian Asian immigrants in Leicester City, UK</article-title>. <source>Br J Rheumatol</source> <year>1992</year>; <volume>31</volume>: <fpage>679</fpage>–<lpage>682</lpage>.</citation></ref>
<ref id="bibr12-0961203311434937"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Merrell</surname><given-names>M</given-names></name><name><surname>Shulman</surname><given-names>LE</given-names></name></person-group>. <article-title>Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus</article-title>. <source>J Chronic Dis</source> <year>1955</year>; <volume>1</volume>: <fpage>12</fpage>–<lpage>32</lpage>.</citation></ref>
<ref id="bibr13-0961203311434937"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abu-Shakra</surname><given-names>M</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Gough</surname><given-names>J</given-names></name></person-group>. <article-title>Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death</article-title>. <source>J Rheumatol</source> <year>1995</year>; <volume>22</volume>: <fpage>1259</fpage>–<lpage>1264</lpage>.</citation></ref>
<ref id="bibr14-0961203311434937"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peschken</surname><given-names>CA</given-names></name><name><surname>Esdaile</surname><given-names>JM</given-names></name></person-group>. <article-title>Systemic lupus erythematosus in North American Indians: a population based study</article-title>. <source>J Rheumatol</source> <year>2000</year>; <volume>27</volume>: <fpage>1884</fpage>–<lpage>1891</lpage>.</citation></ref>
<ref id="bibr15-0961203311434937"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stahl-Hallengren</surname><given-names>C</given-names></name><name><surname>Jonsen</surname><given-names>A</given-names></name><name><surname>Nived</surname><given-names>O</given-names></name><name><surname>Sturfelt</surname><given-names>G</given-names></name></person-group>. <article-title>Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis</article-title>. <source>J Rheumatol</source> <year>2000</year>; <volume>27</volume>: <fpage>685</fpage>–<lpage>691</lpage>.</citation></ref>
<ref id="bibr16-0961203311434937"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cervera</surname><given-names>R</given-names></name><name><surname>Khamashta</surname><given-names>MA</given-names></name><name><surname>Font</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Morbidity and mortality in systemic lupus erythematosus during a 10‐year period: a comparison of early and late manifestations in a cohort of 1,000 patients</article-title>. <source>Medicine (Baltimore)</source> <year>2003</year>; <volume>82</volume>: <fpage>299</fpage>–<lpage>308</lpage>.</citation></ref>
<ref id="bibr17-0961203311434937"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>CC</given-names></name><name><surname>Mak</surname><given-names>A</given-names></name><name><surname>Chu</surname><given-names>WP</given-names></name><name><surname>To</surname><given-names>CH</given-names></name><name><surname>Wong</surname><given-names>SN</given-names></name></person-group>. <article-title>Long-term survival of southern Chinese patients with systemic lupus erythematosus: a prospective study of all age-groups</article-title>. <source>Medicine (Baltimore)</source> <year>2005</year>; <volume>84</volume>: <fpage>218</fpage>–<lpage>224</lpage>.</citation></ref>
<ref id="bibr18-0961203311434937"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Malaviya</surname><given-names>AN</given-names></name><name><surname>Singh</surname><given-names>RR</given-names></name><name><surname>Singh</surname><given-names>YN</given-names></name><name><surname>Adya</surname><given-names>CM</given-names></name><name><surname>Kakkar</surname><given-names>R</given-names></name></person-group>. <article-title>Survival in patients with systemic lupus erythematosus in India</article-title>. <source>Rheumatol Int</source> <year>1992</year>; <volume>12</volume>: <fpage>107</fpage>–<lpage>109</lpage>.</citation></ref>
<ref id="bibr19-0961203311434937"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murali</surname><given-names>R</given-names></name><name><surname>Jeyaseelan</surname><given-names>L</given-names></name><name><surname>Rajaratnam</surname><given-names>S</given-names></name><name><surname>John</surname><given-names>L</given-names></name><name><surname>Ganesh</surname><given-names>A</given-names></name></person-group>. <article-title>Systemic lupus erythematosus in Indian patients: prognosis, survival and life expectancy</article-title>. <source>Natl Med J India</source> <year>1997</year>; <volume>10</volume>: <fpage>159</fpage>–<lpage>164</lpage>.</citation></ref>
<ref id="bibr20-0961203311434937"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>M</given-names></name><name><surname>Clarke</surname><given-names>AM</given-names></name><name><surname>Bruce</surname><given-names>IN</given-names></name><name><surname>Symmons</surname><given-names>D</given-names></name></person-group>. <article-title>The prevalence and incidence of biopsy-proven lupus nephritis in the UK</article-title>. <source>Arthritis Rheum</source> <year>2006</year>; <volume>54</volume>: <fpage>2963</fpage>–<lpage>2969</lpage>.</citation></ref>
<ref id="bibr21-0961203311434937"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jara</surname><given-names>LJ</given-names></name><name><surname>Irigoyen</surname><given-names>L</given-names></name><name><surname>Ortiz</surname><given-names>MJ</given-names></name><name><surname>Zazueta</surname><given-names>B</given-names></name><name><surname>Bravo</surname><given-names>G</given-names></name><name><surname>Espinoza</surname><given-names>LR</given-names></name></person-group>. <article-title>Prolactin and interleukin-6 in neuropsychiatric lupus erythematosus</article-title>. <source>Clin Rheumatol</source> <year>1998</year>; <volume>17</volume>: <fpage>110</fpage>–<lpage>114</lpage>.</citation></ref>
<ref id="bibr22-0961203311434937"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>DM</given-names></name><name><surname>Su</surname><given-names>WL</given-names></name><name><surname>Chu</surname><given-names>SJ</given-names></name></person-group>. <article-title>The expression and significance of intracellular T helper cytokines in systemic lupus erythematosus</article-title>. <source>Immunol Invest</source> <year>2002</year>; <volume>31</volume>: <fpage>1</fpage>–<lpage>12</lpage>.</citation></ref>
<ref id="bibr23-0961203311434937"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Antiga</surname><given-names>E</given-names></name><name><surname>Del Bianco</surname><given-names>E</given-names></name><name><surname>Difonzo</surname><given-names>E</given-names></name><name><surname>Fabbri</surname><given-names>P</given-names></name><name><surname>Caproni</surname><given-names>M</given-names></name></person-group>. <article-title>Serum levels of the regulatory cytokines transforming growth factor-β and interleukin-10 are reduced in patients with discoid lupus erythematosus</article-title>. <source>Lupus</source> <year>2011</year>; <volume>20</volume>: <fpage>556</fpage>–<lpage>560</lpage>.</citation></ref>
<ref id="bibr24-0961203311434937"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Theofilopoulos</surname><given-names>AN</given-names></name><name><surname>Koundouris</surname><given-names>S</given-names></name><name><surname>Kono</surname><given-names>DH</given-names></name><name><surname>Lawson</surname><given-names>BR</given-names></name></person-group>. <article-title>The role of IFN-g in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity</article-title>. <source>Arthritis Res</source> <year>2001</year>; <volume>3</volume>: <fpage>136</fpage>–<lpage>141</lpage>.</citation></ref>
<ref id="bibr25-0961203311434937"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tackey</surname><given-names>E</given-names></name><name><surname>Lipsky</surname><given-names>PE</given-names></name><name><surname>Illei</surname><given-names>GG</given-names></name></person-group>. <article-title>Rationale for interleukin-6 blockade in systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>2004</year>; <volume>13</volume>: <fpage>339</fpage>–<lpage>343</lpage>.</citation></ref>
<ref id="bibr26-0961203311434937"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blenman</surname><given-names>KR</given-names></name><name><surname>Duan</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>IL-10 regulation of lupus in the NZM2410 murine model</article-title>. <source>Lab Invest</source> <year>2006</year>; <volume>86</volume>: <fpage>1136</fpage>–<lpage>1148</lpage>.</citation></ref>
<ref id="bibr27-0961203311434937"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arora</surname><given-names>V</given-names></name><name><surname>Mondal</surname><given-names>AM</given-names></name><name><surname>Grover</surname><given-names>R</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Chattopadhyay</surname><given-names>P</given-names></name><name><surname>Das</surname><given-names>N</given-names></name></person-group>. <article-title>Modulation of CR1 transcript in systemic lupus erythematosus (SLE) by IFN-g and immune complex</article-title>. <source>Mol Immunol</source> <year>2007</year>; <volume>44</volume>: <fpage>1733</fpage>–<lpage>1739</lpage>.</citation></ref>
<ref id="bibr28-0961203311434937"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kidd</surname><given-names>P</given-names></name></person-group>. <article-title>Th1/Th2 Balance: the hypothesis, its limitations, and implications for health and disease</article-title>. <source>Altern Med Rev</source> <year>2003</year>; <volume>8</volume>: <fpage>223</fpage>–<lpage>246</lpage>.</citation></ref>
<ref id="bibr29-0961203311434937"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khalifeh</surname><given-names>MS</given-names></name><name><surname>Al-Rukibat</surname><given-names>R</given-names></name><name><surname>Hananeh</surname><given-names>W</given-names></name><name><surname>Boumezrag</surname><given-names>A</given-names></name><name><surname>Okour</surname><given-names>O</given-names></name></person-group>. <article-title>Investigation of the role of tumour necrosis factor-{alpha}, interleukin-1{beta}, interleukin-10, nitric oxide and rheumatoid factor-immunoglobulin M in a rat model of arthritis</article-title>. <source>Lab Anim</source> <year>2010</year>; <volume>44</volume>: <fpage>143</fpage>–<lpage>149</lpage>.</citation></ref>
<ref id="bibr30-0961203311434937"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>EM</given-names></name><name><surname>Cohen</surname><given-names>AS</given-names></name><name><surname>Fries</surname><given-names>JF</given-names></name><etal/></person-group>. <article-title>The 1982 revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1982</year>; <volume>25</volume>: <fpage>1271</fpage>–<lpage>1277</lpage>.</citation></ref>
<ref id="bibr31-0961203311434937"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>MC</given-names></name></person-group>. <article-title>Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1997</year>; <volume>40</volume>: <fpage>1725</fpage>–<lpage>1725</lpage>.</citation></ref>
<ref id="bibr32-0961203311434937"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lacki</surname><given-names>JK</given-names></name><name><surname>Leszczynski</surname><given-names>P</given-names></name><name><surname>Kelemen</surname><given-names>J</given-names></name><name><surname>Muller</surname><given-names>W</given-names></name><name><surname>Mackiewicz</surname><given-names>SH</given-names></name></person-group>. <article-title>Cytokine concentration in serum of lupus erythematosus patients: the effect on acute phase response</article-title>. <source>J Med</source> <year>1997</year>; <volume>28</volume>: <fpage>99</fpage>–<lpage>107</lpage>.</citation></ref>
<ref id="bibr33-0961203311434937"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Viallard</surname><given-names>JF</given-names></name><name><surname>Pellegrin</surname><given-names>JL</given-names></name><name><surname>Ranchin</surname><given-names>V</given-names></name></person-group>. <article-title>Th1 (IL-2, interferon-gamma (IFN-γ)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE)</article-title>. <source>Clin Exp Immunol</source> <year>1999</year>; <volume>115</volume>: <fpage>189</fpage>–<lpage>195</lpage>.</citation></ref>
<ref id="bibr34-0961203311434937"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gröndal</surname><given-names>G</given-names></name><name><surname>Gunnarsson</surname><given-names>I</given-names></name><name><surname>Rönnelid</surname><given-names>J</given-names></name><name><surname>Rogberg</surname><given-names>S</given-names></name><name><surname>Klareskog</surname><given-names>L</given-names></name><name><surname>Lundberg</surname><suffix>I</suffix></name></person-group>. <article-title>Cytokine production, serum levels and disease activity in systemic lupus erythematosus</article-title>. <source>Clin Exp Rheumatol</source> <year>2000</year>; <volume>18</volume>: <fpage>565</fpage>–<lpage>570</lpage>.</citation></ref>
<ref id="bibr35-0961203311434937"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chun</surname><given-names>HY</given-names></name><name><surname>Chung</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>HA</given-names></name><etal/></person-group>. <article-title>Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus</article-title>. <source>J Clin Immunol</source> <year>2007</year>; <volume>27</volume>: <fpage>461</fpage>–<lpage>466</lpage>.</citation></ref>
<ref id="bibr36-0961203311434937"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>T</given-names></name><name><surname>Leu</surname><given-names>SJ</given-names></name><name><surname>Huang</surname><given-names>CJ</given-names></name><etal/></person-group>. <article-title>Anti-ribosomal phosphoprotein autoantibody triggers interleukin-10 overproduction via phosphatidylinositol 3-kinase-dependent signalling pathways in lipopolysaccharide-activated macrophages</article-title>. <source>Immunology</source> <year>2009</year>; <volume>127</volume>: <fpage>91</fpage>–<lpage>102</lpage>.</citation></ref>
<ref id="bibr37-0961203311434937"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>R</given-names></name><name><surname>Pawlak</surname><given-names>CR</given-names></name><name><surname>Mikeska</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Systemic lupus erythematosus and rheumatoid arthritis patients differ from healthy controls in their cytokine pattern after stress exposure</article-title>. <source>Rheumatology</source> <year>2001</year>; <volume>40</volume>: <fpage>868</fpage>–<lpage>875</lpage>.</citation></ref>
<ref id="bibr38-0961203311434937"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Waal Malefyt</surname><given-names>R</given-names></name><name><surname>Abrams</surname><given-names>J</given-names></name><name><surname>Bennett</surname><given-names>B</given-names></name><name><surname>Figdor</surname><given-names>CG</given-names></name><name><surname>de Vries</surname><given-names>JE</given-names></name></person-group>. <article-title>Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes</article-title>. <source>J Exp Med</source> <year>1991</year>; <volume>174</volume>: <fpage>1209</fpage>–<lpage>1220</lpage>.</citation></ref>
<ref id="bibr39-0961203311434937"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bogdan</surname><given-names>C</given-names></name><name><surname>Vodovotz</surname><given-names>Y</given-names></name><name><surname>Nathan</surname><given-names>C</given-names></name></person-group>. <article-title>Macrophage deactivation by interleukin 10</article-title>. <source>J Exp Med</source> <year>1991</year>; <volume>174</volume>: <fpage>1549</fpage>–<lpage>1555</lpage>.</citation></ref>
<ref id="bibr40-0961203311434937"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gazzinelli</surname><given-names>RT</given-names></name><name><surname>Oswald</surname><given-names>IP</given-names></name><name><surname>James</surname><given-names>SL</given-names></name><name><surname>Sher</surname><given-names>A</given-names></name></person-group>. <article-title>IL-10 inhibits parasite killing and nitrogen oxide production by IFN-gamma-activated macrophages</article-title>. <source>J Immunol</source> <year>1992</year>; <volume>148</volume>: <fpage>1792</fpage>–<lpage>1796</lpage>.</citation></ref>
<ref id="bibr41-0961203311434937"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>JS</given-names></name><name><surname>Morrissey</surname><given-names>PJ</given-names></name><name><surname>Grabstein</surname><given-names>KH</given-names></name><name><surname>Mohler</surname><given-names>KM</given-names></name><name><surname>Anderson</surname><given-names>D</given-names></name><name><surname>Reed</surname><given-names>SG</given-names></name></person-group>. <article-title>Interleukin 10 and interferon gamma regulation of experimental <italic>Trypanosoma cruzi</italic> infection</article-title>. <source>J Exp Med</source> <year>1992</year>; <volume>175</volume>: <fpage>169</fpage>–<lpage>174</lpage>.</citation></ref>
<ref id="bibr42-0961203311434937"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Waal Malefyt</surname><given-names>R</given-names></name><name><surname>Figdor</surname><given-names>CG</given-names></name><etal/></person-group>. <article-title>Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10</article-title>. <source>J Immunol</source> <year>1993</year>; <volume>151</volume>: <fpage>6370</fpage>–<lpage>6381</lpage>.</citation></ref>
<ref id="bibr43-0961203311434937"><label>43</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Delves</surname><given-names>P</given-names></name><name><surname>Roitt</surname><given-names>I</given-names></name></person-group>. <source>Encyclopedia of immunology</source>, <edition>2nd edn</edition>. <publisher-loc>San Diego</publisher-loc>: <publisher-name>Academic Press</publisher-name>, <year>1998, p. 103</year>.</citation></ref>
<ref id="bibr44-0961203311434937"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ishida</surname><given-names>H</given-names></name><name><surname>Muchamuel</surname><given-names>T</given-names></name><name><surname>Sakaguchi</surname><given-names>S</given-names></name><name><surname>Andrade</surname><given-names>S</given-names></name><name><surname>Menon</surname><given-names>S</given-names></name><name><surname>Howard</surname><given-names>M</given-names></name></person-group>. <article-title>Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice</article-title>. <source>J Exp Med</source> <year>1994</year>; <volume>179</volume>: <fpage>305</fpage>–<lpage>310</lpage>.</citation></ref>
<ref id="bibr45-0961203311434937"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yap</surname><given-names>DY</given-names></name><name><surname>Lai</surname><given-names>KN</given-names></name></person-group>. <article-title>Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances</article-title>. <source>J Biomed Biotechnol</source> <year>2010</year><fpage>365083</fpage>–<lpage>365093</lpage>.</citation></ref>
<ref id="bibr46-0961203311434937"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Llorente</surname><given-names>L</given-names></name><name><surname>Zou</surname><given-names>W</given-names></name><name><surname>Levy</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Role of Interleukin-10 in the B-lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus</article-title>. <source>J Exp Med</source> <year>1995</year>; <volume>181</volume>: <fpage>839</fpage>–<lpage>844</lpage>.</citation></ref>
<ref id="bibr47-0961203311434937"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>YB</given-names></name><name><surname>Lee</surname><given-names>SK</given-names></name><name><surname>Kim</surname><given-names>DS</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Song</surname><given-names>CH</given-names></name></person-group>. <article-title>Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus</article-title>. <source>Clin Exp Rheumatol</source> <year>1998</year>; <volume>16</volume>: <fpage>283</fpage>–<lpage>288</lpage>.</citation></ref>
<ref id="bibr48-0961203311434937"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>El-Sayed</surname><given-names>M</given-names></name><name><surname>Nofal</surname><given-names>E</given-names></name><name><surname>al Mokadem</surname><given-names>S</given-names></name><name><surname>al Makhzangy</surname><given-names>I</given-names></name><name><surname>Gaballah</surname><given-names>H</given-names></name><name><surname>Akl</surname><given-names>H</given-names></name></person-group>. <article-title>Correlative study of serum Th1/Th2 cytokines levels in patients with systemic lupus erythematosus with SLEDAI</article-title>. <source>Egypt Dermatol Online J</source> <year>2008</year>; <volume>4</volume>: <fpage>3</fpage>–<lpage>19</lpage>.</citation></ref>
<ref id="bibr49-0961203311434937"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sabat</surname><given-names>R</given-names></name><name><surname>Grütz</surname><given-names>G</given-names></name><name><surname>Warszawska</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Biology of interleukin-10</article-title>. <source>Cytokine Growth Factor Rev</source> <year>2010</year>; <volume>21</volume>: <fpage>331</fpage>–<lpage>344</lpage>.</citation></ref>
<ref id="bibr50-0961203311434937"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SW</given-names></name><name><surname>Hong</surname><given-names>YS</given-names></name><name><surname>Chun</surname><given-names>CM</given-names></name><etal/></person-group>. <article-title>Anti-inflammatory effects of IL-4 and IL-10 on human polymorphonuclear leukocytes</article-title>. <source>J Korean Med Sci</source> <year>2002</year>; <volume>17</volume>: <fpage>7</fpage>–<lpage>14</lpage>.</citation></ref>
<ref id="bibr51-0961203311434937"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calvani</surname><given-names>N</given-names></name><name><surname>Richards</surname><given-names>HB</given-names></name><name><surname>Tucci</surname><given-names>M</given-names></name><name><surname>Pannarale</surname><given-names>G</given-names></name><name><surname>Silvestris</surname><given-names>F</given-names></name></person-group>. <article-title>Up-regulation of IL-18 and predominance of a Th1 immune response is a hallmark of lupus nephritis</article-title>. <source>Clin Exp Immunol</source> <year>2004</year>; <volume>138</volume>: <fpage>171</fpage>–<lpage>178</lpage>.</citation></ref>
<ref id="bibr52-0961203311434937"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gómez</surname><given-names>D</given-names></name><name><surname>Correa</surname><given-names>PA</given-names></name><name><surname>Gómez</surname><given-names>LM</given-names></name><name><surname>Cadena</surname><given-names>J</given-names></name><name><surname>Molina</surname><given-names>JF</given-names></name><name><surname>Anaya</surname><given-names>JM</given-names></name></person-group>. <article-title>Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor alpha protective?</article-title> <source>Semin Arthritis Rheum</source> <year>2004</year>; <volume>33</volume>: <fpage>404</fpage>–<lpage>413</lpage>.</citation></ref>
<ref id="bibr53-0961203311434937"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Kanayama</surname><given-names>Y</given-names></name><name><surname>Negoro</surname><given-names>N</given-names></name><name><surname>Okamura</surname><given-names>M</given-names></name><name><surname>Takeda</surname><given-names>T</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name></person-group>. <article-title>Serum levels of interferons in patients with systemic lupus erythematosus</article-title>. <source>Clin Exp Immunol</source> <year>1987</year>; <volume>70</volume>: <fpage>562</fpage>–<lpage>569</lpage>.</citation></ref>
<ref id="bibr54-0961203311434937"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Al-Janadi</surname><given-names>M</given-names></name><name><surname>Al-Balla</surname><given-names>S</given-names></name><name><surname>Al-Dalaan</surname><given-names>A</given-names></name><name><surname>Raziuddin</surname><given-names>S</given-names></name></person-group>. <article-title>Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases</article-title>. <source>J Clin Immunol</source> <year>1993</year>; <volume>13</volume>: <fpage>58</fpage>–<lpage>67</lpage>.</citation></ref>
<ref id="bibr55-0961203311434937"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tokano</surname><given-names>Y</given-names></name><name><surname>Morimoto</surname><given-names>S</given-names></name><name><surname>Kaneko</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE) – relation to Th1- and Th2-derived cytokines</article-title>. <source>Clin Exp Immunol</source> <year>1999</year>; <volume>116</volume>: <fpage>169</fpage>–<lpage>173</lpage>.</citation></ref>
<ref id="bibr56-0961203311434937"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robak</surname><given-names>E</given-names></name><name><surname>Smolewski</surname><given-names>P</given-names></name><name><surname>Wozniacka</surname><given-names>A</given-names></name><name><surname>Sysa-Jedrzejowska</surname><given-names>A</given-names></name><name><surname>Stepien</surname><given-names>H</given-names></name><name><surname>Robak</surname><given-names>T</given-names></name></person-group>. <article-title>Relationship between peripheral blood dendritic cells and cytokines involved in the pathogenesis of systemic lupus erythematosus</article-title>. <source>Eur Cytokine Netw</source> <year>2004</year>; <volume>15</volume>: <fpage>222</fpage>–<lpage>230</lpage>.</citation></ref>
<ref id="bibr57-0961203311434937"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>KW</given-names></name><name><surname>de Waal Malefyt</surname><given-names>R</given-names></name><name><surname>Coffman</surname><given-names>RL</given-names></name><name><surname>O Garra</surname><given-names>A</given-names></name></person-group>. <article-title>Interleukin-10 and the interleukin-10 receptor</article-title>. <source>Annu Rev Immunol</source> <year>2001</year>; <volume>19</volume>: <fpage>683</fpage>–<lpage>765</lpage>.</citation></ref>
<ref id="bibr58-0961203311434937"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Emilie</surname><given-names>D</given-names></name><name><surname>Llorente</surname><given-names>L</given-names></name><name><surname>Galanaud</surname><given-names>P</given-names></name></person-group>. <article-title>Cytokines and systemic lupus erythematosus</article-title>. <source>Ann Med Intern</source> <year>1996</year>; <volume>147</volume>: <fpage>480</fpage>–<lpage>484</lpage>.</citation></ref>
<ref id="bibr59-0961203311434937"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davas</surname><given-names>EM</given-names></name><name><surname>Tsirogianni</surname><given-names>A</given-names></name><name><surname>Kappou</surname><given-names>I</given-names></name><name><surname>Karamitsos</surname><given-names>D</given-names></name><name><surname>Economidou</surname><given-names>I</given-names></name><name><surname>Dantis</surname><given-names>PC</given-names></name></person-group>. <article-title>Serum IL-6, TNFα, p55 srTNFα, p75 srTNFα, srIL-2α levels and disease activity in systemic lupus erythematosus</article-title>. <source>Clin Rheumatol</source> <year>1999</year>; <volume>18</volume>: <fpage>17</fpage>–<lpage>22</lpage>.</citation></ref>
<ref id="bibr60-0961203311434937"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahmoudn</surname><given-names>RA</given-names></name><name><surname>El-Gendi</surname><given-names>HI</given-names></name><name><surname>Ahmed</surname><given-names>HH</given-names></name></person-group>. <article-title>Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus</article-title>. <source>Clin Biochem</source> <year>2005</year>; <volume>38</volume>: <fpage>134</fpage>–<lpage>141</lpage>.</citation></ref>
<ref id="bibr61-0961203311434937"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sabry</surname><given-names>A</given-names></name><name><surname>Sheashaa</surname><given-names>H</given-names></name><name><surname>El-Husseini</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: its correlation with disease activity</article-title>. <source>Cytokine</source> <year>2006</year>; <volume>35</volume>: <fpage>148</fpage>–<lpage>153</lpage>.</citation></ref>
<ref id="bibr62-0961203311434937"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Swadzba</surname><given-names>J</given-names></name><name><surname>Iwaniec</surname><given-names>T</given-names></name><name><surname>Musial</surname><given-names>J</given-names></name></person-group>. <article-title>Increased level of tumor necrosis factor-alpha in patients with antiphospholipid syndrome: marker not only of inflammation but also of the prothrombotic state</article-title>. <source>Rheumatol Int</source> <year>2011</year>; <volume>31</volume>: <fpage>307</fpage>–<lpage>313</lpage>.</citation></ref>
<ref id="bibr63-0961203311434937"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keystone</surname><given-names>EC</given-names></name><name><surname>Ware</surname><given-names>CF</given-names></name></person-group>. <article-title>Tumor necrosis factor and anti-tumor necrosis factor therapies</article-title>. <source>J Rheumatol Suppl</source> <year>2010</year>; <volume>85</volume>: <fpage>27</fpage>–<lpage>39</lpage>.</citation></ref>
<ref id="bibr64-0961203311434937"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>BB</given-names></name><name><surname>Kohr</surname><given-names>WJ</given-names></name><name><surname>Hass</surname><given-names>PE</given-names></name><etal/></person-group>. <article-title>Human tumor necrosis factor. Production, purification, and characterization</article-title>. <source>J Biol Chem</source> <year>1985</year>; <volume>260</volume>: <fpage>2345</fpage>–<lpage>2354</lpage>.</citation></ref>
<ref id="bibr65-0961203311434937"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oppenheim</surname><given-names>JJ</given-names></name><name><surname>Neta</surname><given-names>R</given-names></name></person-group>. <article-title>Pathophysiological roles of cytokines in development, immunity, and inflammation</article-title>. <source>FASEB J</source> <year>1994</year>; <volume>8</volume>: <fpage>158</fpage>–<lpage>162</lpage>.</citation></ref>
<ref id="bibr66-0961203311434937"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aringer</surname><given-names>M</given-names></name><name><surname>Smolen</surname><given-names>JS</given-names></name></person-group>. <article-title>The role of tumor necrosis factor-alpha in systemic lupus erythematosus</article-title>. <source>Arthritis Res Ther</source> <year>2008</year>; <volume>10</volume>: <fpage>202</fpage>–<lpage>210</lpage>.</citation></ref>
<ref id="bibr67-0961203311434937"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tucci</surname><given-names>M</given-names></name><name><surname>Lombardi</surname><given-names>L</given-names></name><name><surname>Richards</surname><given-names>HB</given-names></name><name><surname>Dammacco</surname><given-names>F</given-names></name><name><surname>Silvestris</surname><given-names>F</given-names></name></person-group>. <article-title>Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis</article-title>. <source>Clin Exp Immunol</source> <year>2008</year>; <volume>154</volume>: <fpage>247</fpage>–<lpage>254</lpage>.</citation></ref>
<ref id="bibr68-0961203311434937"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lourenço</surname><given-names>EV</given-names></name><name><surname>La Cava</surname><given-names>A</given-names></name></person-group>. <article-title>Cytokines in systemic lupus erythematosus</article-title>. <source>Curr Mol Med</source> <year>2009</year>; <volume>9</volume>: <fpage>242</fpage>–<lpage>254</lpage>.</citation></ref>
<ref id="bibr69-0961203311434937"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kassi</surname><given-names>E</given-names></name><name><surname>Moutsatsou</surname><given-names>P</given-names></name></person-group>. <article-title>Estrogen receptor signaling and its relationship to cytokines in systemic lupus erythematosus</article-title>. <source>J Biomed Biotechnol</source> <year>2010</year><fpage>317452</fpage>–<lpage>317464</lpage>.</citation></ref>
<ref id="bibr70-0961203311434937"><label>70</label><citation citation-type="other"><comment>Apostolidis SA, Lieberman LA, Kis-Toth K, Crispín JC, Tsokos GC. The dysregulation of cytokine networks in systemic lupus erythematosus. <italic>J Interferon Cytokine Res</italic> (in press)</comment>.</citation></ref>
<ref id="bibr71-0961203311434937"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akahoshi</surname><given-names>M</given-names></name><name><surname>Nakashima</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>th1/th2 balance of peripheral t helper cells in systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1999</year>; <volume>42</volume>: <fpage>1644</fpage>–<lpage>1648</lpage>.</citation></ref>
<ref id="bibr72-0961203311434937"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Llorente</surname><given-names>L</given-names></name><name><surname>Richard Patin</surname><given-names>Y</given-names></name><name><surname>Fior</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjögren’s syndrome and systemic lupus erythematosus. A potential mechanism of B cell hyperactivity and autoimmunity</article-title>. <source>Arthritis Rheum</source> <year>1994</year>; <volume>37</volume>: <fpage>1647</fpage>–<lpage>1655</lpage>.</citation></ref>
<ref id="bibr73-0961203311434937"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arican</surname><given-names>O</given-names></name><name><surname>Aral</surname><given-names>M</given-names></name><name><surname>Sasmaz</surname><given-names>S</given-names></name><name><surname>Ciragil</surname><given-names>P</given-names></name></person-group>. <article-title>Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity</article-title>. <source>Mediators Inflamm</source> <year>2005</year>; <volume>2005</volume>: <fpage>273</fpage>–<lpage>279</lpage>.</citation></ref>
</ref-list>
</back>
</article>